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The United States Pharmacopeia (USP) has
proposed changes to control the levels of
elemental impurities in bio/pharmaceutical
d rugs  tha t  a re  inc luded  in  two
new USP General Chapters: USP <232>
Elemental Impurities-Limits, and USP <233>
Elemental Impurities-Procedures. These
chapters are anticipated to replace USP General
Chapter USP <231> Heavy Metals.
The proposed tests measure individual metals
as opposed to a group of metals that were
measured by the previous sulfide precipitation
method USP <231>. Most manufacturers are
likely to have little or no data on individual metal
elemental impurities in their excipient batches.
Consequently, there is no assurance that such
data, even assuming that it could be generated
across multiple manufacturers/lots/geographi-
cal locations in a short period of time, will meet
the proposed limits. It should be noted that
these proposed limits are themselves solely set
based on toxicity (permissible daily exposure,
PDE) data with no regard to whether or not
they are achievable, especially in mined or
natural sourced excipients. Should it turn out
that  one or more of the proposed individual
metal specifications are not achievable, this may
force the withdrawal of mined or naturally
sourced excipients from the pharmaceutical
markets, which by all accounts, constitutes a
minor portion of the revenue stream for such
commoditized and mass produced materials. 
Although USP <232> recognizes the
phenomenon of speciation in metals, the
proposed methods can detect only the total
metal content (not individual species) and
assume the presence of only the inorganic form
in the test material. The proposed methods
therefore do not seem to be able to distinguish
between the bioavailable fraction versus the
total metal content in the test material.
Recombinant modified bacteria expressing
luminescence encoding genes have been
developed for ecotoxicological analysis that can
specifically detect bioavailable fractions of
cadmium, mercury and lead. Preliminary studies
using the most commonly mined and naturally
sourced excipients would have readily
established what portion of the heavy metals in
these processed materials was bioavailable. This
information could have been used as a basis for
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setting data driven meaningful specficiations.
Measuring total metal content is not useful if a
very small fraction is actually bioavailable, in
which case the existing USP <231> may very
well suffice to adequately control metal
impurities. 
The  In te rna t iona l  Confe r ence  on
Harmonization (ICH) is working on a new
guideline on metal impurities, ICH Q3D. This
guideline will ensure that specifications for
metal impurities will be consistent across the
United States, Europe and Japan. The approved
guideline is expected to be available in 2014 at
the earliest. Stakeholders have persistently
expressed their opinion that the USP guidelines
in USP <232> and USP <233> be harmo-
nized, or at least take into account the ICH
effort so that USP requirements align in large
part with those that will eventually be applied
with the finalization of ICH Q3D.
USP <232> states that testing is not needed if
manufacturers can demonstrate the absence of
impurities by validated processes and supply-
chain control. The caveat of validated processes
presumably incorporates individual metal
testing. Given that there may exist significant
variability in individual metals for mined or
naturally sourced excipients (mined or
harvested from different geographical regions
or even from different locations in the same
quarry or plantation), there can be no assurance
that a particular batch may consistently meet
specifications for any individual metal,
regardless of the (scramble to) develop
validated analytical procedures; that themselves
require costly instrumentation. Therefore, the
argument that the newly developed chapters
allow for a risk based management approach is
misleading. A better approach would have been
to allow for outliers in an overall robust
statistical risk analysis from various batches
across different locations.
USP <232> states that the proposed limits are
based on chronic exposure. Does this imply
that chemotherapeutic, antibiotic, anesthetic or
antimalarial medicines, or those that are not for
prophylactic use, would be exempt from these
limits? For those patients on long term life
saving cardiovascular, antidiabetic or antiHIV
medications, would it matter if the total metal
content of sulfide precipitation enabled heavy
metal impurities in the drug product was below
a reasonably stringent threshold, and had been
so for decades without any ill effects, or would
they want metal impurities to be individually
quantified? What would be the risk to benefit
ratio of doing so? Even assuming that particular
metals in this sulfide precipitation enabling
cocktail were greater than their PDE limits,
while meeting the (admittedly subjective) total
metal content specification of  USP <231>,
there may be other methods available that
would not necessarily require expensive
instrumentation such as ICP-AES or ICP-OES
to measure individual metals. Such methods can
be developed based on fractional precipitation
of individual metals due to their different
solubility products and would, in all probability,
be implemented using an inexpensive titrimetric
method in conjunction with ion specific
electrodes. A large sample size (2 grams for a
limit of 10 parts per million (ppm)) for
excipients is not unduly cumbersome (as it is in
the case of proteins or peptide APIs).
Therefore, the testing can incorporate large
sample sizes in leu of more expensive
instrumented methodology if applicable.
This brings us to the last, but not (by any
means) the least important question. Is this
nuanced level of regulation really necessary?
The mean daily intake of arsenic in food for
adults has been estimated to range from 16.7 to
129 µg ((1) and references therein). A number
of estimates based on figures for per capita
consumption have been made of the daily
dietary lead intake, for example, 27 µg/day in
Sweden, 66 µg/day in Finland, and 53.8 µg/day
from food for adolescents and adults in
Canada. In some countries, dietary intakes of
lead as high as 500 µg/day have been reported.
The regular consumption of wine can also
result in a significant increase in lead intake, an
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average level of 73 µg/l has been reported ((2)
and references therein). The proposed
individual oral PDE limits for arsenic and lead
in USP <232> seems unduly low in this
respect. Levels of heavy metals in (<125 µm
readily redispersable and respirable fraction) the
street dust of Cairo exceed the PDE limits with
lead, arsenic and cadmium levels of 234.6, 1.52
and 0.82 ppm respectively. These are especially
dangerous because they are present in easily
absorbable smaller inhalable fractions and
people are exposed to them on a daily (chronic)
basis. The proposed tests apply to the United
States, Europe and Japan, pharmaceutical
products produced in these jurisdictions are
sold across the world. While recognizing that
these examples can hardly be used as
justification for not controlling heavy metals in
excipients, it may be prudent to ask whether
regulation at this non-consequential, yet widely
differential a scale, would make any significant
difference to the heavy metal ingestion of the
general global populace, given the exponentially
rising levels of urbanization, industrialization
and of motorized vehicles. 
This detailed a level of regulation introduces
unnecessary logistical problems. Some of these
include the necessity to ‘pick and choose’ lots
for sale or consumption based on their
individual heavy metal content and the
(bio)pharmaceutical products they are destined
to be part of. Where the total limit for an
individual metal is exceeded, additional testing
is necessary to demonstrate that the
bioavailable species (depending on the route of
administration) meets the specifications.
Designat ion of addit ional  in-house
identification numbers, inventory control and
management for excipient lots is necessary
depending on their destination of use, i.e., in
oral, parenteral or inhalation formulation
batches. All these have to fall in place in
conjunction with API stability considerations,
additional impurity specification regulations and
whether or not monographs are harmonized
across the various jurisdictions, necessitating
additional documentation, verification,
validation (and if necessary, requalification)
,bureaucracy and an increase in the cost of
medicines.
By all accounts, analytical limit testing in USP
<231> has rarely produced positive results,
implying that no individual metal was present at
a higher specified limit.  Although there were
issues with the accuracy and recovery of metals,
particularly mercury, using the sulfide precipi-
tation method, does a risk that is neither clearly
identified nor significant to the health of
patients as demonstrated over time, necessitate
imposition of new analytical methodology that
has concomitant specifications that impact
supply chains and has repercussions far beyond
its ostensible modest purview? Regardless of
whether or not  USP <232> and  USP <233>
will eventually harmonize with ICH Q3D, new
regulation and mandates must have clearly
defined and measurable value that is
significantly better than that existing, that is
acknowledged by all stakeholders, a reasonable
risk to reward outcome, and ease of adoption
and implementation. 
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